BIOCON

BIOCON

approved_indications FDA Approved Biologics and Pending Applications

Fulphila®

pegfilgrastim-jmdb
aBL 761075

MYL-1402O

bevacizumab
MYL-1402O Approval Pending

Ogivri®

trastuzumab-dkst
aBL 761074

Semglee®

insulin glargine-yfgn
aBL 210605 / aBL 761201

approved_indications Approved Foreign Follow-On Biologics / Biosimilars

Biosimilars Approved In Canada

Fulphila® (pegfilgrastim) (Mylan / Biocon) (May-2019) Kirsty (BGP Pharma (Viatris)) (October-2021)Ogivri® (trastuzumab) (Mylan / Biocon) (May-2019)

Biosimilars Approved In The E.U.

Abevmy (bevacizumab) (Biocon / Viatris) (April-2021)Fulphila® (pegfilgrastim) (Mylan / Biocon) (November-2018)Kirsty (previously Kixelle) (insulin aspart) (Viatris / Biocon) (February-2021)Ogivri® (trastuzumab) (Mylan / Biocon) (December-2018)Semglee® (insulin glargine) (Mylan / Biocon) (March-2018)

Biosimilars Approved In Australia

Fulphila® (pegfilgrastim) (Alphapharm / Mylan / Biocon) (August-2018)Ogivri® (trastuzumab) (Mylan / Biocon) (December-2018) Semglee® (insulin glargine) (Mylan / Biocon) (March-2018)

Biosimilars Approved In Japan

Insulin glargine BS (insulin glargine) (Biocon / Fujifilm Pharma) (March-2016)

Biosimilars Approved In South Korea

Ogivri® (trastuzumab) (Alvogen Korea) (August-2020)

approved_indications Inter Partes Review Proceedings

GENENTECH CABILLYIPR2016-00710
LANTUS / LANTUS SOLOSTAR / SEMGLEEIPR2017-01526
IPR2017-01528
IPR2018-01670
IPR2018-01675
IPR2018-01676
IPR2018-01677
IPR2018-01678
IPR2018-01679
IPR2018-01680
IPR2018-01682
IPR2018-01684
IPR2018-01696
IPR2019-00122

related articles Related News Articles

Spotlight On: Neulasta® (pegfilgrastim) / Fulphila® (pegfilgrastim-jmdb) / Udenyca® (pegfilgrastim-cbqv) / Ziextenzo® (pegfilgrastim-bmez) / Nyvepria® (pegfilgrastim-apgf) April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D. April 30, 2022
Spotlight On: Herceptin® (trastuzumab) / Ogivri® (trastuzumab-dkst) / Herzuma® (trastuzumab-pkrb) / Ontruzant® (trastuzumab-dttb) / Trazimera® (trastuzumab-qyyp) / Kanjinti® (trastuzumab-anns) April Breyer Menon; Frederick C. Millett; Corinne E. Atton; Robert S. Schwartz, Ph.D. April 30, 2022
Spotlight On: Lantus® / Lantus® SoloSTAR® (insulin glargine recombinant) / Basaglar® (insulin glargine) / Semglee® (insulin glargine) / Rezvoglar™ (insulin glargine-aglr) April Breyer Menon; Damineh Morsali, Ph.D.; Corinne E. Atton; Robert S. Schwartz, Ph.D. April 30, 2022
Viatris and Biocon Launch First Interchangeable Insulin in the U.S. April Breyer Menon November 30, 2021
FDA Approves Boehringer Ingelheim’s Cyltezo® as Interchangeable with Humira® April Breyer Menon October 25, 2021
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – July 2021 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong August 11, 2021
FDA Approves Semglee® (Insulin Glargine) as the First Interchangeable Biosimilar in the U.S. April Breyer Menon July 29, 2021
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – April 2021 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong May 12, 2021
Boehringer Ingelheim Applies for Interchangeability Designation for Cyltezo® (adalimumab-adbm) April Breyer Menon April 26, 2021
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – February 2021 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong March 9, 2021
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – December 2020 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong January 12, 2021
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – August 2020 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong September 9, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – March 2020 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D.; Ha Kung Wong April 8, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – December 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D.; Ha Kung Wong January 7, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – May 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. June 6, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – April 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. May 7, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – November 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. December 11, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – October 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. November 12, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – September 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. October 6, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – June 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. July 6, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – December 2017 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. January 8, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – July 2017 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. July 26, 2017

Methodology

Information contained in the Venable Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable Fitzpatrick BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha